Published on Tuesday March 09, 2021

Smooth Drug Development February 2021 News Release

We are working on the following new projects:

• We signed a WO for CTD modules preparation with our global Sponsor.

• We signed 2 contracts for specification documents (INN: Vardenafil and INN: Fulvestrant).

We are happy to reach the following milestones in our projects:

• 90% of the sites were closed in the clinical trial with Risperidone.

• We prepared a CSR in the oncology clinical trial for patients with AML.

• Enrollment was started in a III phase trial with Nimesulide.

• Smooth finished all activities in a study with flu vaccine.